期刊文献+

rm hTNF-α联合吉西他滨杀伤人肺腺癌细胞A549作用研究 被引量:5

The killing effect of rm hTNF-α combined with gemcitabine on human lung adenocarcinom a cells A 549
下载PDF
导出
摘要 背景与目的目前,晚期非小细胞肺癌患者化疗效果已达平台,生物治疗与化疗联合使用可明显改善此类患者的治疗效果。本课题旨在研究rmhTNF-α联合吉西他滨对人肺腺癌细胞A549的杀伤作用及其作用机制。方法应用CCK-8法检测不同浓度rmhTNF-α及吉西他滨对A549细胞抑制率,应用细胞生长曲线描述经rmhTNF-α、吉西他滨干预过的A549细胞增殖情况,应用流式细胞仪检测各药物处理组48h的细胞周期分布及凋亡率,并用光学显微镜及透射电子显微镜观察A549细胞形态及超微结构。结果CCK-8检测结果及细胞生长曲线均提示rmhTNF-α不仅具有抑制A549细胞生长作用,而且可以增强吉西他滨对A549细胞杀伤作用;FCM显示两药联合组可促使A549细胞阻滞在S期,降低G2/M期比率;凋亡比率以吉西他滨+rmhTNF-α组最明显,光镜及电镜下观察结果均能明显观察到A549细胞呈凋亡形态学改变。结论rmhTNF-α通过诱导人肺腺癌细胞A549细胞凋亡及细胞周期阻滞,从而增强吉西他滨对其的杀伤作用。 Background and objective At present clinical researches has proven that the chemotherapeutic effect on advanced non-small cell lung cancer (NSCLC) has gotten to plateau. Biotherapy combined with chemotherapy could improve curative effect on advanced NSCLC obviously. The project is aiming at exploring the killing effect and the mechanism of rmhTNF-α in combination with gemcitabine on human lung adenocarcinoma cell line A549. Methods CCK-8 was used to detect the inhibition ratio of rmhTNF-α and gemcitabine ce...
出处 《中国肺癌杂志》 CAS 2008年第4期495-499,共5页 Chinese Journal of Lung Cancer
关键词 RM HTNF-Α 吉西他滨 肺肿瘤 凋亡 细胞周期 rmhTNF-α Gemcitabine Lung neoplasms Apoptosis Cell cycle
  • 相关文献

参考文献3

  • 1周清华,鄢希,任莉,李潞,邱萌,杨玉琼,罗德云,黄雯霞,刘鲁明,陈震,孟志强,王雅杰,傅强,徐阳,杨林军,李明众,李恩孝,李毅,姚煜,张祥福,刘星,卢辉山,张茂宏,王秀问,于学军,秦凤展,郑荣生,陈余清,毕明宏.注射用重组改构人肿瘤坏死因子联合化疗药物治疗非小细胞肺癌的多中心Ⅲ期临床试验[J].中国肺癌杂志,2003,6(4):264-267. 被引量:17
  • 2R. Kurdow,B. Schniewind,S. Zoefelt,L. Boenicke,A.-S. Boehle,P. Dohrmann,H. Kalthoff. Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression[J] 2005,Langenbeck’s Archives of Surgery(3):243~248
  • 3Zhong-Wei Xu,Helmut Friess,Markus W. Büchler,Marc Solioz. [J] 2002,Cancer Chemotherapy and Pharmacology(6):504~510

二级参考文献10

  • 1[1]Lee KY, Chang W, Qiu D, et al. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem,1999,274(19)∶13451-13455.
  • 2[2]Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst,1996,88 (19)∶1383-1392.
  • 3[3]Lasek W, Giermasz A, Kuc K, et al. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer,1996,66(3)∶374-379.
  • 4[5]Chcialowski A, Targowski T, Bajera I, et al. Tumor necrosis factor alpha: Phase Ⅰ and phase Ⅲ clinical trials. Pol Merkuriusz Lek,1997,2(12)∶396-399.
  • 5[6]Tomita A, Fuchino Y, Otsuka K, et al. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res,1998,18(5D)∶3937-3939.
  • 6[7]Du Bois JS, Trehu EG, Mier JW, et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol,1997,15(3)∶1052-1062.
  • 7[8]Libutti SK, Barlett DL, Fraker DL, et al. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg,2000,191(5)∶519-530.
  • 8[9]Nakamoto T, Inagawa H, Takagi K, et al. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res,2000,20(6A)∶4087-4096.
  • 9[10]Fukushima T, Yamamoto M, Ikeda K, et al. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res,1998,18(5D)∶3965-3970.
  • 10周清华,侯梅,李潞,任莉,邱萌,杨玉琼,黄雯霞,陈震,孟志强,宋明志,李明众,李恩孝,李毅,姚煜,郑知文,刘星,张祥福,卢辉山,张茂宏,王秀问,于学军.新型重组人肿瘤坏死因子治疗非小细胞肺癌的多中心Ⅱ期临床随机试验[J].中国肺癌杂志,2003,6(1):42-45. 被引量:33

共引文献16

同被引文献58

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部